Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic and diagnostic evaluation of HSPG2 gene expression in oral squamous cell carcinoma: A case-control study.

Archives of oral biology·2026
Same author

Boosting the immune response and protective efficacy of inactivated PRV vaccine using cGAMP as a mucosal adjuvant.

BMC veterinary research·2026
Same author

Parallel Activation and Interference CRISPR (PAIR) with Sequencing Uncovers DNA Repair Networks Guiding Precision Cell Engineering.

bioRxiv : the preprint server for biology·2026
Same author

Design, synthesis, and biological evaluation of ALK5 PROTAC degraders for pulmonary fibrosis.

Bioorganic chemistry·2026
Same author

Peripheral T-Cell Lymphomas in Southern Taiwan: Epidemiology, Treatment Patterns, and Long-Term Outcomes.

EJHaem·2026
Same author

Tailoring topological altermagnetic spin texture via interfacial exchange coupling in quasi-2D CrSb/(Bi, Sb)<sub>2</sub>Te<sub>3</sub> thin film.

Nature communications·2026

Related Experiment Video

Updated: Jun 24, 2025

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

7.7K

Targeting FGFR for cancer therapy.

Pei Zhang1, Lin Yue2, QingQing Leng1

  • 1Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041, Sichuan, China.

Journal of Hematology & Oncology
|June 3, 2024
PubMed
Summary

Fibroblast Growth Factor Receptor (FGFR) signaling is crucial for cell functions and cancer development. FGFR inhibitors show promise in oncology, but challenges like resistance require further research for optimal patient outcomes.

Keywords:
Clinical trialsDrug resistanceFDA-approved drugsFGFRTumors

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.8K

Related Experiment Videos

Last Updated: Jun 24, 2025

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

7.7K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.8K

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • The Fibroblast Growth Factor Receptor (FGFR) signaling pathway regulates essential cellular processes like proliferation, differentiation, and survival.
  • Aberrant FGFR signaling is implicated in the pathogenesis of various human cancers, making it a significant therapeutic target.

Purpose of the Study:

  • To provide a comprehensive review of FGFR function, signaling, and alterations in tumorigenesis.
  • To analyze clinical trials and FDA-approved FGFR inhibitors in oncology.
  • To discuss challenges and future directions for FGFR-targeted therapies.

Main Methods:

  • Comprehensive literature review of FGFR signaling pathways and their role in cancer.
  • Analysis of pivotal Phase 2 and 3 clinical trials for FGFR inhibitors.
  • Review of FDA-approved FGFR inhibitor drugs, their mechanisms, and clinical outcomes.

Main Results:

  • FGFR dysregulation is a key driver in numerous cancers.
  • Several FGFR inhibitors have demonstrated efficacy and safety in clinical trials.
  • Four FGFR inhibitors are FDA-approved, with distinct molecular mechanisms and clinical successes.

Conclusions:

  • FGFR-targeted therapies hold significant potential for improving cancer patient prognosis.
  • Overcoming resistance mechanisms and optimizing treatment strategies are critical for maximizing therapeutic benefits.
  • Continued research is essential to refine FGFR-centric approaches and enhance clinical outcomes.